SCHEMBL5404165

SCHEMBL5404165

C/C(=N\c1ccc(C)cc1C)c1cccc(/C(C)=N/c2ccc(C)cc2C)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 3/20 0.40
GAA P10253 3/20 0.40
ALDH1A1 P00352 3/20 0.40
THRB P10828 2/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
MPI P34949 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606037 1.00 MAPT (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5589484 0.98 MAPT (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15082904 0.97 MAPT (0.46) MAPTNPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL3296200 0.97 MAPT (0.46) MAPTNPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL3296202 0.97 MAPT (0.46) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15082892 0.94 MAPT (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL31173575 0.90 MAPT (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL19887496 0.89 NPC1 (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5693762 0.88 NPC1 (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15082905 0.87 DHODH (0.38) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP claimed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP claimed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO claimed
EP-2797862-B1 OLEFIN OLIGOMERIZATION METHODS CHEVRON PHILLIPS CHEMICAL CO LP (US) 2021-04-07 EP disclosed
US-20180051103-A1 OLIGOMER PRODUCTION METHOD AND CATALYST JXTG NIPPON OIL & ENERGY CORPORATION (JP) 2018-02-22 US disclosed
US-9586872-B2 Olefin oligomerization methods CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-03-07 US disclosed
US-9586872-B2 Olefin oligomerization methods CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2017-03-07 US disclosed
EP-2572783-B1 Method of separating pentene-2 from a C5 cut containing pentene-2 and pentene-1 by selective oligomerisation of the pentene-1 IFP Energies Nouvelles (FR) 2014-11-12 EP disclosed
US-20130172651-A1 Olefin Oligomerization Methods CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 US disclosed
WO-2013101387-A1 OLEFIN OLIGOMERIZATION METHODS CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 WO disclosed
US-20130172651-A1 Olefin Oligomerization Methods CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2013-07-04 US disclosed
US-20130072732-A1 METHOD OF SEPARATING BUTENE-2 FROM A C4 CUT CONTAINING BUTENE-2 AND BUTENE-1 BY SELECTIVE OLIGOMERIZATION OF BUTENE-1 IFP Energies Nouvelles (FR) 2013-03-21 US disclosed
US-20130072732-A1 METHOD OF SEPARATING BUTENE-2 FROM A C4 CUT CONTAINING BUTENE-2 AND BUTENE-1 BY SELECTIVE OLIGOMERIZATION OF BUTENE-1 IFP Energies Nouvelles (FR) 2013-03-21 US disclosed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US disclosed
US-7223893-B2 Linear alpha-olefin dimers possessing substantial linearity CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) 2007-05-29 US disclosed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP disclosed
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. 2006-03-02 US disclosed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP disclosed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO disclosed
US-20020177744-A1 Linear alpha-olefin dimers possessing substantial linearity CHEVRON PHILLIPS CHEMICAL COMPANY LP 2002-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180051103-A1 OLIGOMER PRODUCTION METHOD AND CATALYST OR51E2, NOD2, MSMO1 MAPT 1380/4885NPC1 2034/4885RAB9A 3107/4885
US-20130072732-A1 METHOD OF SEPARATING BUTENE-2 FROM A C4 CUT CONTAINING BUTENE-2 AND BUTENE-1 BY SELECTIVE OLIGOMERIZATION OF BUTENE-1 C9, BBOX1, BTN3A1 MAPT 1958/4885NPC1 2911/4885RAB9A 4840/4885
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization MLX, LOX, LMTK3 MAPT 585/4885NPC1 3851/4885RAB9A 4633/4885
US-20130172651-A1 Olefin Oligomerization Methods COG4, OSTC, COG8 MAPT 1260/4885NPC1 2809/4885RAB9A 4007/4885
US-20020177744-A1 Linear alpha-olefin dimers possessing substantial linearity ADH1A, ALOX12, ALOX15B MAPT 696/4885NPC1 4520/4885RAB9A 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.